|
|
|
|
|
The Niche
|
Stem Cell & Regenerative Med Newsletter
|
|
|
|
|
|
Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA
|
|
|
|
A days ago the news came about Mesoblast not getting FDA approval for its MSC product for GvHD. The MSC area has had a rough few years with various clinical trials including for COVID. The "stem cells for heart disease" arena has also had a tough time. Here's more news along these lines: BioCardia pauses enrollment in PhIII trial of heart failure stem cell …
|
|
|
|
|
|
|
|
Hoping for approval, Mesoblast says FDA wants new remestemcel-L trial
|
|
|
|
Australian biotech Mesoblast has had a rollercoaster ride working toward FDA approval of its mesenchymal cell therapy product remestemcel-L. They are seeking approval for use in patients with graft-versus-host disease (GvHD). More specifically, it is intended for pediatric patients with steroid-refractory acute graft versus host disease, or SR-aGVHD. This is a serious condition and new treatment options are urgently needed. Could …
|
|
|
|
|
|
|
|
Some surprises from new analysis of Altos Labs papers
|
|
|
|
Altos Labs is an intriguing multi-institution experiment in so-called rejuvenation research all rolled into one biotech. This relatively new entity headquartered in California has multiple Nobel laureates in the biomedical field in leadership. Even more importantly it has a large group of great researchers leading its individual research labs. This all leads to high expectations, but their goal is a …
|
|
|
|
|
|
